baf1086 Search Results


baf1086  (R&D Systems)
91
R&D Systems baf1086
Baf1086, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/baf1086/product/R&D Systems
Average 91 stars, based on 1 article reviews
baf1086 - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier
biotinylated anti human pd 1 affinity  (R&D Systems)
93
R&D Systems biotinylated anti human pd 1 affinity
Polyfunctionality and phenotype of HIV-specific CD8+ T cells following stimulation with HIV-infected CD4+ T-cell targets for 6 h. (A) Summary pie charts show median percentages of total responding CD8+ T cells that express IFN-γ, MIP-1β, CD107, IL-2, or TNF-α in LTNP (n = 23, first row) and Rx <50 (n = 47, second row). Scatter plots (third row) depict the percent expression of each function for each LTNP and Rx <50. Horizontal lines represent median values. Comparisons were made using the Wilcoxon two-sample test. Only significant P values are shown. (B) Summary pie charts (top row) show median percentages of responding CD8+ T cells grouped according to the number of simultaneous functions executed: five functions, red; four, yellow; three, green; two, blue; and one, black. Individual functional subsets are shown in the summary bar graph (bottom row) for LTNP (red) and Rx <50 (blue). Background responses to uninfected targets have been subtracted. A line extends from the median to the upper interquartile range. Asterisks indicate significant differences between response pairs: ***, P < 0.001; **, P < 0.01; and *, P < 0.05. (C) Summary pie charts (first and second rows) and scatter plots (third row) show the fraction of the total responding CD8+ T cells expressing CCR7, CD45RA, <t>or</t> <t>PD-1</t> for the same patients as in panel A. (D) Summary pie charts and bar graph show median percentages of responding CD8+ T cells expressing various combinations of the three phenotypic markers. CCR7+ subsets are shown in shades of teal, and CCR7− subsets are shown in shades of pink.
Biotinylated Anti Human Pd 1 Affinity, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotinylated anti human pd 1 affinity/product/R&D Systems
Average 93 stars, based on 1 article reviews
biotinylated anti human pd 1 affinity - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


Polyfunctionality and phenotype of HIV-specific CD8+ T cells following stimulation with HIV-infected CD4+ T-cell targets for 6 h. (A) Summary pie charts show median percentages of total responding CD8+ T cells that express IFN-γ, MIP-1β, CD107, IL-2, or TNF-α in LTNP (n = 23, first row) and Rx <50 (n = 47, second row). Scatter plots (third row) depict the percent expression of each function for each LTNP and Rx <50. Horizontal lines represent median values. Comparisons were made using the Wilcoxon two-sample test. Only significant P values are shown. (B) Summary pie charts (top row) show median percentages of responding CD8+ T cells grouped according to the number of simultaneous functions executed: five functions, red; four, yellow; three, green; two, blue; and one, black. Individual functional subsets are shown in the summary bar graph (bottom row) for LTNP (red) and Rx <50 (blue). Background responses to uninfected targets have been subtracted. A line extends from the median to the upper interquartile range. Asterisks indicate significant differences between response pairs: ***, P < 0.001; **, P < 0.01; and *, P < 0.05. (C) Summary pie charts (first and second rows) and scatter plots (third row) show the fraction of the total responding CD8+ T cells expressing CCR7, CD45RA, or PD-1 for the same patients as in panel A. (D) Summary pie charts and bar graph show median percentages of responding CD8+ T cells expressing various combinations of the three phenotypic markers. CCR7+ subsets are shown in shades of teal, and CCR7− subsets are shown in shades of pink.

Journal: Journal of Virology

Article Title: Defective Human Immunodeficiency Virus-Specific CD8 + T-Cell Polyfunctionality, Proliferation, and Cytotoxicity Are Not Restored by Antiretroviral Therapy ▿

doi: 10.1128/JVI.01153-09

Figure Lengend Snippet: Polyfunctionality and phenotype of HIV-specific CD8+ T cells following stimulation with HIV-infected CD4+ T-cell targets for 6 h. (A) Summary pie charts show median percentages of total responding CD8+ T cells that express IFN-γ, MIP-1β, CD107, IL-2, or TNF-α in LTNP (n = 23, first row) and Rx <50 (n = 47, second row). Scatter plots (third row) depict the percent expression of each function for each LTNP and Rx <50. Horizontal lines represent median values. Comparisons were made using the Wilcoxon two-sample test. Only significant P values are shown. (B) Summary pie charts (top row) show median percentages of responding CD8+ T cells grouped according to the number of simultaneous functions executed: five functions, red; four, yellow; three, green; two, blue; and one, black. Individual functional subsets are shown in the summary bar graph (bottom row) for LTNP (red) and Rx <50 (blue). Background responses to uninfected targets have been subtracted. A line extends from the median to the upper interquartile range. Asterisks indicate significant differences between response pairs: ***, P < 0.001; **, P < 0.01; and *, P < 0.05. (C) Summary pie charts (first and second rows) and scatter plots (third row) show the fraction of the total responding CD8+ T cells expressing CCR7, CD45RA, or PD-1 for the same patients as in panel A. (D) Summary pie charts and bar graph show median percentages of responding CD8+ T cells expressing various combinations of the three phenotypic markers. CCR7+ subsets are shown in shades of teal, and CCR7− subsets are shown in shades of pink.

Article Snippet: PD-1 staining was performed using a biotinylated anti-human PD-1 affinity-purified goat immunoglobulin G primary stain (R&D Systems, Inc., Minneapolis, MN) and a Qdot 655 streptavidin conjugate as secondary stain (Invitrogen Molecular Probes).

Techniques: Infection, Expressing, Functional Assay